Microbot Medical has announced positive results from its pivotal ACCESS-PVI trial, showcasing the potential of its Liberty surgical robot in performing endovascular procedures. The study, conducted at top U.S. centers including Sloan Kettering, Baptist Hospital of Miami, and Brigham and Women’s Hospital, confirmed the system’s technical success and safety.
Key Findings:
- 100% success in robotic navigation across 20 procedures.
- No adverse device events were reported.
- Achieved a mean 92% reduction in radiation exposure.
- Median navigation time to target: 3 minutes.
Liberty is designed for catheter-based neurovascular, cardiovascular, and peripheral procedures. Its compact, fully disposable, and remotely operated design may allow it to become the first democratized solution for endovascular robotics.
Microbot submitted Liberty to the FDA in December 2024 and expects clearance and commercial launch by mid-2025.
Follow MEDWIRE.AI for robotic surgery breakthroughs and device trial updates.
